【摘要】 目的:探讨替吉奥(S-1)用于非小细胞肺癌(NSCLC)术后辅助化疗效果和安全性。方法:全面搜索关于替吉奥用于NSCLC术后辅助化疗的相关文献,并按照制定的纳入标准筛选出符合要求的文献,然后分别提取各文献的NSCLC术后使用替吉奥辅助化疗的完成率、2年无复发生存(RFS)率、严重不良反应发生率,最后使用Stata 15软件对所提取的数据进行Meta分析。结果:本研究分析了纳入的10项临床试验共计420例患者,对于替吉奥用于NSCLC术后辅助化疗有三个主要发现:(1)荟萃的完成率为61.0%;(2)荟萃的2年RFS率为78.0%;(3)绝大部分的严重不良反应的发生率均<5%,除了中性粒细胞减少(6.2%)。结论:NSCLC采用替吉奥辅助化疗具有较好的完成率和2年RFS率,不良反应少。因此,对于年老体弱难以耐受化疗毒副反应的NSCLC患者,可以考虑将替吉奥作为辅助化疗的可选方案之一。更多还原

【Abstract】 Objective:To investigate the efficacy and safety of adjuvant chemotherapy with S-1 in patients with non-small cell lung cancer (NSCLC).Method:Relevant articles about adjuvant chemotherapy with S-1 in patients with NSCLC were thoroughly collected.Subsequently,eligible studies were identified according to the inclusion criteria.Moreover,completion rate,2-year relapse-free survival rates (2-yRFS rate) and incidence of severe adverse events were extracted.Eventually,this meta-analysis was performed via Stata 15 software.Result:In the present Meta-analysis included 10 eligible studies incorporating 420 patients,three major findings were reported:(1) the pooled completion rate was calculated to be 61.0%;(2) the pooled 2-yRFS rate was 78.0%;(3) most of severe adverse events were found in less than 5% of patients,except that neutropenia events were found in 6.2% of patients.Conclusion:S-1 adjuvant chemotherapy for treating NSCLC provided good curative effect of better completion rate and 2-yRFS,with less adverse reactions.Therefore,S-1 adjuvant chemotherapy regimen is recommended for frail older people with NSCLC who are unable to tolerate certain side effects.更多还原